GlobeNewsWire
29 Jun 2026, 11:40 UTC · 11w ago
Verdict
Headline takes no side. We score HELP +1.00 across five claims — strongly bullish.
+1.00strongly bullish
More positive than 98% of ticker scores this week
What the story claims
5 claims · scored −1 bearish … +1 bullish
The Phase 3 APPROACH study for HLP003 in Major Depressive Disorder is on track for topline data readout in Q4 2026.
More positive than 98% of claims this week
Helus Pharma closed a $50 million underwritten offering to fund its balance sheet and the second Phase 3 trial, EMBRACE.
So whatSecuring capital reduces immediate liquidity risk and provides the runway necessary to execute late-stage trials.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More positive than 76% of claims this week
Phase 2 signal detection results for HLP004 in Generalized Anxiety Disorder showed a ~10-point improvement in HAM-A scores over standard of care at 6 weeks.
So whatPositive early data for a secondary pipeline asset increases the company's overall valuation and diversifies clinical risk.
More positive than 62% of claims this week
The Phase 3 APPROACH study has surpassed 88% enrollment.
So whatHigh enrollment rates reduce the risk of trial delays and support the timeline for the Q4 2026 readout.
More positive than 49% of claims this week
The company is progressing HLP005 toward candidate selection, with a viable candidate expected in the second half of 2027.
More positive than 40% of claims this week
Which stocks this story touches
More positive than 98% of ticker scores this week
The company successfully raised $50 million, reported positive Phase 2 and 3 clinical trial progress, and strengthened its leadership team.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
3d ago
+90.9%
Price agrees with the score
$12.37 vs $6.48 close before publication (Jun 26) · not market-adjusted
HELP chart →
